London · Delayed Price · Currency is GBP · Price in GBX Theracryf Statistics
Total Valuation
Theracryf has a market cap or net worth of GBP 4.51 million. The enterprise value is 1.02 million.
| Market Cap | 4.51M |
| Enterprise Value | 1.02M |
Important Dates
The last earnings date was Wednesday, December 3, 2025.
| Earnings Date | Dec 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Theracryf has 2.15 billion shares outstanding. The number of shares has increased by 300.38% in one year.
| Current Share Class | 2.15B |
| Shares Outstanding | 2.15B |
| Shares Change (YoY) | +300.38% |
| Shares Change (QoQ) | +228.79% |
| Owned by Insiders (%) | 28.74% |
| Owned by Institutions (%) | 56.10% |
| Float | 1.27B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.94 |
| P/TBV Ratio | 1.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.51 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.29
| Current Ratio | 2.29 |
| Quick Ratio | 2.29 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -53.79% and return on invested capital (ROIC) is -37.57%.
| Return on Equity (ROE) | -53.79% |
| Return on Assets (ROA) | -28.77% |
| Return on Invested Capital (ROIC) | -37.57% |
| Return on Capital Employed (ROCE) | -46.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -223,222 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -144,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -74.86% in the last 52 weeks. The beta is 1.47, so Theracryf's price volatility has been higher than the market average.
| Beta (5Y) | 1.47 |
| 52-Week Price Change | -74.86% |
| 50-Day Moving Average | 0.20 |
| 200-Day Moving Average | 0.23 |
| Relative Strength Index (RSI) | 68.13 |
| Average Volume (20 Days) | 2,757,321 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -2.23M |
| Operating Income | -2.25M |
| Pretax Income | -2.15M |
| Net Income | -2.01M |
| EBITDA | -2.21M |
| EBIT | -2.25M |
| Earnings Per Share (EPS) | -0.00 |
Balance Sheet
The company has 3.50 million in cash and n/a in debt, with a net cash position of 3.50 million or 0.00 per share.
| Cash & Cash Equivalents | 3.50M |
| Total Debt | n/a |
| Net Cash | 3.50M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 4.80M |
| Book Value Per Share | 0.00 |
| Working Capital | 2.35M |
Cash Flow
| Operating Cash Flow | -1.70M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Theracryf does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -300.38% |
| Shareholder Yield | -300.38% |
| Earnings Yield | -44.52% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |